Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
We are focused on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis and asthma.
Leadership
We are led by a globally experienced management team and scientific advisory board with an established track record in the discovery, clinical development and commercialization of respiratory therapies.
Our Focus
Design and development of thiol-saccharides as safe and effective mucolytic agents with favorable properties for inhaled delivery.
Utilization of state-of-the art lung imaging and analysis approaches to identify COPD and asthma patients with clinically silent airway mucus plugs and to measure efficacy of thiol-saccharide mucolytics.
Aer Therapeutics Product Pipeline
